Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voclosporin in FSGS
NCT03598036Phase 2Terminated
- Sponsor
- Aurinia
- Start
- Jun 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of voclosporin in focal segmental glomerulosclerosis (FSGS) (2 cohorts), sponsored by Aurinia. Primary endpoint: Proportion of Subjects With Remission of Proteinuria at 24 weeks. Started Jun 2018; status: terminated.
02
Drugs
voclosporin
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT03598036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03598036.